Mulakan
ReutersReuters

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

RefinitivBacaan kurang dari 1 minit
BCAB

Bioatla Inc BCAB:

  • BIOATLA PRESENTS PROMISING INTERIM DATA FROM ITS PHASE 1 TRIAL WITH BA3182 IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT ESMO 2025

ReutersSaham AS
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini

Lebih berita dari Reuters